:max_bytes(150000):strip_icc()/GettyImages-2160946786-60b895e8980347ce96269c07adeacb24.jpg?w=1920&resize=1920,1363&ssl=1 "Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply | Global News Avenue")
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2160946786-60b895e8980347ce96269c07adeacb24.jpg)
Key Points
- The Food and Drug Administration said the active ingredients of Ozempic and Wegovy are no longer in short supply, and Hims & Hers’ health stock is shocked.
- The company has made a composite version of weight-loss medication under FDA rules that apply to difficult to obtain originals.
- The FDA said it will take action against companies currently producing complex drugs within 90 days.
Hims & Hers Healthy Stake (he) Friday at Food and Drug Administration It says that the active ingredients of Eli Lilly are lacking (Lai)Wegovy and Novo Nordisk (NGOs)Ozempic has been resolved.
Since 2022, it has been considered an over-the-top treatment option for weight loss and type 2 diabetes and has become a popular treatment option.
This may affect Hims & her, which makes Weight loss pills By combining key ingredients in the patented version with other drugs. This is legal, thanks to the FDA rule called 503B, which allows companies to Mass production When it is difficult to obtain the original medicine, compound medicine.
The FDA said it does not intend to take action against 503B drug compounders by 90 days or May 22 to avoid unnecessary damage to patients’ treatment. ”
Hims says it will monitor future shortages
He and hers CEO Andrew Dudum said in an article on X on Friday that the company “will continue to provide personalized treatments permitted by law”, adding that the company “closely monitors potential future shortages” .
This is the Eli Lilly weight loss treatment Mounjaro said in October zepbound (Use active ingredient Tirzepatide, not Semaglutide) no longer On the list of drugs with short supply.
Hims shares fell more than 23% on Friday afternoon, earlier this week after the company announced plans to launch Blood test at home In next year. Shares in Eli Lilly and Nordnono shares rose by less than 1% and more than 5% respectively on Friday.
:max_bytes(150000):strip_icc()/GettyImages-2160946786-60b895e8980347ce96269c07adeacb24.jpg?w=1200&resize=1200,0&ssl=1&description=Hims+%26+Hers+Stock+Drops+as+FDA+Says+Ozempic+and+Wegovy+No+Longer+in+Short+Supply+%7C+Global+News+Avenue){kind=link}